Makadzange Azure Tariro, Gundidza Patricia, Lau Charles, Beta Norest, Myburgh Nellie, Elose Nyasha, James Wilmot, Stanberry Lawrence, Ndhlovu Chiratidzo
Charles River Medical Group, 155 King George Avenue, Avondale, Harare, Zimbabwe.
RTI International, 3040 East Cornwallis Road, Research Triangle Park, Research Triangle, NC 27709, USA.
Vaccines (Basel). 2022 Oct 21;10(10):1767. doi: 10.3390/vaccines10101767.
Vaccination is one of the most effective methods for preventing morbidity and mortality from COVID-19. Vaccine hesitancy has led to a decrease in vaccine uptake; driven by misinformation, fear, and misperceptions of vaccine safety. Whole inactivated vaccines have been used in one-fifth of the vaccine recipients in Africa, however there are limited real-world data on their safety. We evaluated the reported adverse events and factors associated with reported adverse events following vaccination with whole inactivated COVID-19 vaccines-BBiBP-CorV (Sinopharm) and CoronaVac (Sinovac). A quantitative survey evaluating attitudes and adverse events from vaccination was administered to 1016 adults presenting at vaccination centers. Two follow-up telephone interviews were conducted to determine adverse events after the first and second vaccination dose. Overall, the vaccine was well tolerated; 26.0% and 14.4% reported adverse events after the first and second dose, respectively. The most frequent local and systemic adverse events were pain at the injection site and headaches, respectively. Most symptoms were mild, and no participants required hospitalization. Participants who perceived COVID-19 vaccines as safe or had a personal COVID-19 experience were significantly less likely to report adverse events. Our findings provide data on the safety and tolerability of whole inactivated COVID-19 vaccines in an African population, providing the necessary data to create effective strategies to increase vaccination and support vaccination campaigns.
接种疫苗是预防新冠病毒病发病和死亡的最有效方法之一。疫苗犹豫导致疫苗接种率下降，其原因是错误信息、恐惧以及对疫苗安全性的误解。全灭活疫苗已在非洲五分之一的疫苗接种者中使用，然而关于其安全性的实际数据有限。我们评估了接种全灭活新冠疫苗（国药集团中国生物北京生物制品研究所有限责任公司的BBiBP-CorV和科兴生物的CoronaVac）后报告的不良事件以及与报告不良事件相关的因素。对前往疫苗接种中心的1016名成年人进行了一项评估接种态度和不良事件的定量调查。进行了两次随访电话访谈，以确定第一剂和第二剂疫苗接种后的不良事件。总体而言，疫苗耐受性良好；分别有26.0%和14.4%的人在接种第一剂和第二剂疫苗后报告了不良事件。最常见的局部和全身不良事件分别是注射部位疼痛和头痛。大多数症状较轻，没有参与者需要住院治疗。认为新冠疫苗安全或有过新冠病毒病个人经历的参与者报告不良事件的可能性显著较低。我们的研究结果提供了全灭活新冠疫苗在非洲人群中的安全性和耐受性数据，为制定提高疫苗接种率的有效策略和支持疫苗接种运动提供了必要数据。
